SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Vion (formerly Oncorx) interesting play on Gene Therapy
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Keith Feral who wrote (354)12/7/2007 9:08:02 PM
From: buffalodon2003  Read Replies (1) of 370
 
This has been and is a good buy position if hedging longer positions. With the anticipation of the ASH and Cloretazine's Phase II data, this is a good buy through to end of 1st quarter 2008. I have been long at $1.30 pps for few years and would like to get out at $3 which may be a reach by time FDA approves/disapproves application. But irrespective, this anticipation since stock was at +.55 was a good buy up to ASH. I imagine this may cool afterwards, unless results surpass endpoints of trial parameters. Comments!
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News